SS
SRPT icon

Steve Schonfeld’s Sarepta Therapeutics SRPT Stock Holding History

Steve Schonfeld’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-67,500
Closed -$8.18M – 2187
2023
Q3 		$8.18M Buy
+67,500
New +$7.63M 0.06% 405
2021
Q1 		– Sell
-70,000
Closed -$11.9M – 2108
2020
Q4 		$11.9M Buy
+70,000
New +$10.4M 0.16% 172

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Steve Schonfeld's SRPT Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 138,004 shares worth $2.48M. The stake represents 0.01% of the portfolio and ranks #958 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in SRPT as recently as Q4 2025.

Steve Schonfeld first reported a position in SRPT in Q2 2016 and has held it in 33 quarters since. The position peaked at $18.9M in Q4 2022. 320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Steve Schonfeld held 138,004 shares of Sarepta Therapeutics worth $2.48M as of Q2 2026.
  • Sarepta Therapeutics was a new Steve Schonfeld position in Q2 2026.
  • Sarepta Therapeutics made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #958 holding.
  • Steve Schonfeld first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 33 quarters since.
  • Steve Schonfeld's Sarepta Therapeutics position peaked at $18.9M in Q4 2022.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.